Catheter Precision, Inc.(VTAK)Earnings, Financials & Key Ratios
VTAK•AMEX
$0.89
$1M mkt cap·Price updated May 7, 2026
AboutCatheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.Show more
- Revenue$420K-5.0%
- EBITDA-$9M+88.0%
- Net Income-$17M+76.4%
- EPS (Diluted)-6.68+48.6%
- Gross Margin90%-3.4%
- EBITDA Margin-2174.76%+87.4%
- Operating Margin-2676.9%+84.9%
- Net Margin-3962.62%+75.2%
- ROE-101.02%+78.2%
- ROIC-58.82%+94.3%
- Debt/Equity0.15+766.4%
- Interest Coverage-123.55
VTAK Key Insights
Catheter Precision, Inc. (VTAK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 40.6% through buybacks
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Sales declining 43.4% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
VTAK Price & Volume
Catheter Precision, Inc. (VTAK) stock price & volume — 10-year historical chart
Loading chart...
VTAK Growth Metrics
Catheter Precision, Inc. (VTAK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-43.35%
3 Years167.27%
TTM82.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-48.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM52.83%
Return on Capital
10 Years-172.81%
5 Years-185.72%
3 Years-224.83%
Last Year-41.68%
VTAK Peer Comparison
Catheter Precision, Inc. (VTAK) competitors in Cardiovascular and heart rhythm devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATRC | 1.41B | 27.80 | -115.83 | 14.88% | -0.83% | -0.95% | 0.18 | |
 BEAT | 34.93M | 0.87 | -1.40 | -5.71% | ||||
 IRTC | 4.1B | 124.87 | -89.83 | 26.24% | -3.53% | -20.6% | 4.79 | |
 ELMD | 222.39M | 26.86 | 31.23 | 16.97% | 13.06% | 19.79% | 0.00 | |
 BSX | 84.08B | 56.58 | 29.16 | 19.87% | 14.4% | 12.4% | 0.51 | |
 ABT | 151.3B | 87.01 | 11.39 | 4.59% | 31.88% | 27.26% | 0.32 | |
 MDT | 99.94B | 77.96 | 21.60 | 3.62% | 13% | 9.45% | 0.59 | |
 JNJ | 536.23B | 222.51 | 38.43 | 4.3% | 27.26% | 31.69% | 0.51 |
Compare VTAK vs Peers
Catheter Precision, Inc. (VTAK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VTAK Income Statement
Catheter Precision, Inc. (VTAK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 5.98M | 5.87M | 6.26M | 7.2M | 259K | 22K | 14K | 442K | 420K | 730K |
| Revenue Growth % | - | -1.77% | 6.59% | 15.06% | -96.4% | -91.51% | -36.36% | 3057.14% | -4.98% | 82.96% |
| Cost of Goods Sold | 3.14M | 4.17M | 4.21M | 8.85M | 2.17M | 1.56M | 161K | 30K | 42K | 582K |
| COGS % of Revenue | 52.51% | 70.95% | 67.22% | 122.93% | 838.61% | 7090.91% | 1150% | 6.79% | 10% | - |
| Gross Profit | 2.84M▲ 0% | 1.71M▼ 39.9% | 2.05M▲ 20.3% | -1.65M▼ 180.5% | -1.91M▼ 15.9% | -1.54M▲ 19.6% | -147K▲ 90.4% | 412K▲ 380.3% | 378K▼ 8.3% | 148K▲ 0% |
| Gross Margin % | 47.49% | 29.05% | 32.78% | -22.93% | -738.61% | -6990.91% | -1050% | 93.21% | 90% | 20.27% |
| Gross Profit Growth % | - | -39.92% | 20.29% | -180.5% | -15.87% | 19.6% | 90.44% | 380.27% | -8.25% | - |
| Operating Expenses | 7.04M | 19.46M | 33.21M | 56.08M | 33.49M | 27.73M | 26.81M | 78.53M | 11.62M | 14.48M |
| OpEx % of Revenue | 117.74% | 331.6% | 530.78% | 778.98% | 12929.73% | 126036.36% | 191528.57% | 17767.19% | 2766.9% | - |
| Selling, General & Admin | 5.32M | 14.95M | 30.43M | 51.55M | 24.53M | 15.47M | 16.25M | 17.12M | 11.35M | 11.89M |
| SG&A % of Revenue | 89.04% | 254.63% | 486.42% | 716.06% | 9472.2% | 70340.91% | 116071.43% | 3873.76% | 2702.14% | - |
| Research & Development | 1.72M | 4.52M | 2.78M | 4.53M | 8.96M | 12.25M | 6.39M | 475K | 272K | 2.59M |
| R&D % of Revenue | 28.7% | 76.97% | 44.37% | 62.93% | 3457.53% | 55695.45% | 45657.14% | 107.47% | 64.76% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 4.17M | 60.93M | 0 | 0 |
| Operating Income | -4.2M▲ 0% | -17.76M▼ 323.1% | -31.16M▼ 75.5% | -57.73M▼ 85.3% | -35.4M▲ 38.7% | -29.27M▲ 17.3% | -26.96M▲ 7.9% | -78.12M▼ 189.7% | -11.24M▲ 85.6% | -14.33M▲ 0% |
| Operating Margin % | -70.25% | -302.56% | -498% | -801.92% | -13668.34% | -133027.27% | -192578.57% | -17673.98% | -2676.9% | -1963.42% |
| Operating Income Growth % | - | -323.06% | -75.45% | -85.27% | 38.68% | 17.33% | 7.88% | -189.75% | 85.61% | - |
| EBITDA | -4.1M | -17.54M | -30.54M | -55.98M | -33.04M | -27.87M | -26.54M | -76.04M | -9.13M | -12.21M |
| EBITDA Margin % | -68.66% | -298.84% | -488.03% | -777.61% | -12755.21% | -126663.64% | -189571.43% | -17204.52% | -2174.76% | -1673.15% |
| EBITDA Growth % | - | -327.54% | -74.07% | -83.32% | 40.99% | 15.65% | 4.76% | -186.53% | 87.99% | -40.13% |
| D&A (Non-Cash Add-back) | 95K | 218K | 624K | 1.75M | 2.37M | 1.4M | 421K | 2.08M | 2.11M | 2.12M |
| EBIT | -4.2M | -17.76M | -30.81M | -56.69M | -35.4M | -27.25M | -22.79M | -17.18M | -13.41M | -15.68M |
| Net Interest Income | -3K | -4K | 338K | 788K | 21K | -10K | 0 | 347K | -10K | -185K |
| Interest Income | 0 | 0 | 352K | 1.04M | 129K | 0 | 0 | 347K | 81K | 65K |
| Interest Expense | 3K | 4K | 14K | 250K | 108K | 10K | 0 | 0 | 91K | 250K |
| Other Income/Expense | -3K | -4K | 338K | 788K | 88K | 2.01M | 99K | 7.55M | -2.26M | -1.6M |
| Pretax Income | -4.2M▲ 0% | -17.76M▼ 322.9% | -30.82M▼ 73.5% | -56.94M▼ 84.7% | -35.31M▲ 38.0% | -27.26M▲ 22.8% | -26.86M▲ 1.4% | -70.57M▼ 162.7% | -13.5M▲ 80.9% | -15.93M▲ 0% |
| Pretax Margin % | -70.3% | -302.62% | -492.6% | -790.97% | -13634.36% | -123895.45% | -191871.43% | -15966.52% | -3214.76% | -2182.19% |
| Income Tax | 1K | 1K | 10K | 15K | 7K | 4K | 3K | 0 | 3.14M | 1.54M |
| Effective Tax Rate % | -0.02% | -0.01% | -0.03% | -0.03% | -0.02% | -0.01% | -0.01% | 0% | -23.26% | -9.7% |
| Net Income | -4.2M▲ 0% | -17.77M▼ 322.8% | -30.83M▼ 73.6% | -56.96M▼ 84.7% | -36.05M▲ 36.7% | -25.07M▲ 30.4% | -26.86M▼ 7.2% | -70.57M▼ 162.7% | -16.64M▲ 76.4% | -17.38M▲ 0% |
| Net Margin % | -70.31% | -302.64% | -492.76% | -791.18% | -13916.99% | -113954.55% | -191892.86% | -15966.52% | -3962.62% | -2381.1% |
| Net Income Growth % | - | -322.77% | -73.55% | -84.73% | 36.72% | 30.45% | -7.16% | -162.69% | 76.42% | -48.77% |
| Net Income (Continuing) | -4.2M | -17.77M | -30.83M | -56.96M | -35.32M | -27.26M | -26.86M | -70.57M | -16.64M | -17.48M |
| Discontinued Operations | 0 | 0 | 0 | 0 | -725K | 2.19M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -333K |
| EPS (Diluted) | -433.96▲ 0% | -1834.66▼ 322.8% | -4175.51▼ 127.6% | -5416.22▼ 29.7% | -1060.77▲ 80.4% | -248.22▲ 76.6% | -25.98▲ 89.5% | -12.99▲ 50.0% | -6.68▲ 48.6% | -1.32▲ 0% |
| EPS Growth % | - | -322.77% | -127.59% | -29.71% | 80.41% | 76.6% | 89.53% | 50% | 48.58% | 52.83% |
| EPS (Basic) | -433.96 | -1834.66 | -4175.51 | -5416.22 | -1060.77 | -248.22 | -25.98 | -12.99 | -6.68 | - |
| Diluted Shares Outstanding | 9.68K | 9.68K | 7.38K | 10.52K | 33.98K | 101K | 1.03M | 5.5M | 3.26M | 13.21M |
| Basic Shares Outstanding | 9.68K | 9.68K | 7.38K | 10.52K | 33.98K | 101K | 1.03M | 5.5M | 3.26M | 13.21M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VTAK Balance Sheet
Catheter Precision, Inc. (VTAK) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.31M | 10.04M | 69.23M | 36M | 27.62M | 17.09M | 16.84M | 4.16M | 3.29M | 2.47M |
| Cash & Short-Term Investments | 3.92M | 8.24M | 64.31M | 30.58M | 23.91M | 15.04M | 15.86M | 3.56M | 2.87M | 1.07M |
| Cash Only | 3.92M | 8.24M | 64.31M | 14.58M | 23.91M | 15.04M | 15.86M | 3.56M | 2.87M | 1.07M |
| Short-Term Investments | 0 | 0 | 0 | 15.99M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 393K | 517K | 1.32M | 786K | 24K | 21K | 0 | 137K | 70K | 123K |
| Days Sales Outstanding | 24 | 32.15 | 77 | 39.85 | 33.82 | 348.41 | - | 113.13 | 60.83 | 49.13 |
| Inventory | 870K | 1.2M | 2.1M | 2.78M | 877K | 986K | 0 | 44K | 33K | 34K |
| Days Inventory Outstanding | 101.19 | 104.81 | 181.98 | 114.53 | 147.38 | 230.7 | - | 535.33 | 286.79 | 29.16 |
| Other Current Assets | 0 | 0 | 0 | 0 | 1.71M | 0 | 977K | 415K | 316K | 1.24M |
| Total Non-Current Assets | 534K | 1.23M | 4.8M | 8.08M | 5.82M | 3.96M | 0 | 26.57M | 24.48M | 23.01M |
| Property, Plant & Equipment | 506K | 1.16M | 4.76M | 7.88M | 5.7M | 3.92M | 0 | 249K | 196K | 256K |
| Fixed Asset Turnover | 11.81x | 5.06x | 1.32x | 0.91x | 0.05x | 0.01x | - | 1.78x | 2.14x | 3.30x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.32M | 24.27M | 22.74M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 28K | 68K | 45K | 196K | 123K | 36K | 0 | 8K | 8K | 32K |
| Total Assets | 5.84M▲ 0% | 11.27M▲ 92.9% | 74.03M▲ 557.0% | 44.08M▼ 40.5% | 33.44M▼ 24.1% | 21.04M▼ 37.1% | 16.84M▼ 20.0% | 30.74M▲ 82.6% | 27.77M▼ 9.6% | 25.47M▲ 0% |
| Asset Turnover | 1.02x | 0.52x | 0.08x | 0.16x | 0.01x | 0.00x | 0.00x | 0.01x | 0.02x | 0.03x |
| Asset Growth % | - | 92.9% | 556.98% | -40.46% | -24.14% | -37.07% | -20% | 82.56% | -9.65% | -28.56% |
| Total Current Liabilities | 2.71M | 2.63M | 5.95M | 6.81M | 7.76M | 5.39M | 7.58M | 2.47M | 2.08M | 5.33M |
| Accounts Payable | 473K | 426K | 1.13M | 1.53M | 471K | 988K | 92K | 464K | 230K | 1.08M |
| Days Payables Outstanding | 55.02 | 37.33 | 97.63 | 63.18 | 79.15 | 231.17 | 208.57 | 5.65K | 2K | 432.73 |
| Short-Term Debt | 42K | 44K | 293K | 293K | 686K | 0 | 0 | 184K | 177K | 2.07M |
| Deferred Revenue (Current) | 1.74M | 1.71M | 1.72M | 2.03M | 1.8M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 297K | 213K | 1.07M | 1.16M | 1.97M | 2.12M | 369K | 43K | 67K | 2.18M |
| Current Ratio | 1.96x | 3.81x | 11.64x | 5.28x | 3.56x | 3.17x | 2.22x | 1.68x | 1.58x | 1.58x |
| Quick Ratio | 1.64x | 3.36x | 11.28x | 4.88x | 3.45x | 2.99x | 2.22x | 1.67x | 1.56x | 1.56x |
| Cash Conversion Cycle | 70.18 | 99.63 | 161.35 | 91.2 | 102.05 | 347.94 | - | -5K | -1.65K | -354.44 |
| Total Non-Current Liabilities | 3.51M | 16.25M | 1.38M | 4.12M | 4.53M | 1.98M | 0 | 7.07M | 13.93M | 13.7M |
| Long-Term Debt | 65K | 19K | 557K | 265K | 1.58M | 0 | 0 | 0 | 1.5M | 1.41M |
| Capital Lease Obligations | 0 | -15.38M | 0 | 2.62M | 2.26M | 1.98M | 0 | 97K | 13K | 110K |
| Deferred Tax Liabilities | 0 | 15.38M | 0 | 0 | 0 | 0 | 0 | 0 | 3.14M | 8.57M |
| Other Non-Current Liabilities | 2.61M | 81K | 56K | 0 | 0 | 0 | 0 | 6.97M | 9.27M | 31.56M |
| Total Liabilities | 6.22M | 18.88M | 7.33M | 10.93M | 12.29M | 7.37M | 7.58M | 9.54M | 16.01M | 19.02M |
| Total Debt | 107K | 63K | 850K | 3.5M | 4.88M | 2.26M | 0 | 372K | 1.79M | 3.48M |
| Net Debt | -3.81M | -8.17M | -63.47M | -11.09M | -19.02M | -12.78M | -15.86M | -3.19M | -1.08M | 2.41M |
| Debt / Equity | - | - | 0.01x | 0.11x | 0.23x | 0.17x | - | 0.02x | 0.15x | 0.15x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.29x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.20x |
| Interest Coverage | -1399.33x | -4440.00x | -2225.71x | -230.92x | -327.79x | -2926.60x | - | - | -123.55x | -62.72x |
| Total Equity | -380K▲ 0% | -7.62M▼ 1903.9% | 66.7M▲ 976.0% | 33.15M▼ 50.3% | 21.15M▼ 36.2% | 13.67M▼ 35.3% | 9.26M▼ 32.3% | 21.19M▲ 128.9% | 11.76M▼ 44.5% | 6.45M▲ 0% |
| Equity Growth % | - | -1903.95% | 975.97% | -50.3% | -36.21% | -35.34% | -32.28% | 128.87% | -44.52% | -205.76% |
| Book Value per Share | -39.24 | -786.43 | 9033.72 | 3152.34 | 622.34 | 135.38 | 8.96 | 3.86 | 3.60 | 0.49 |
| Total Shareholders' Equity | -380K | -7.62M | 66.7M | 33.15M | 21.15M | 13.67M | 9.26M | 21.19M | 11.76M | 6.78M |
| Common Stock | 1K | 1K | 1K | 1K | 7K | 8K | 0 | 0 | 0 | 0 |
| Retained Earnings | -11.62M | -29.39M | -60.22M | -117.16M | -153.2M | -178.27M | -205.14M | -275.71M | -292.35M | -303.76M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -589K | -775K | -1.31M | 26K | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -333K |
VTAK Cash Flow Statement
Catheter Precision, Inc. (VTAK) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.89M | -5.52M | -18.51M | -33.17M | -28.3M | -27.63M | -22.57M | -20.62M | -9.27M | -9.27M |
| Operating CF Margin % | -31.56% | -94.09% | -295.8% | -460.8% | -10928.19% | -125568.18% | -161200% | -4664.93% | -2207.38% | - |
| Operating CF Growth % | - | -192.84% | -235.11% | -79.24% | 14.68% | 2.4% | 18.31% | 8.64% | 55.04% | -93.49% |
| Net Income | -4.2M | -17.77M | -30.83M | -56.96M | -36.05M | -25.07M | -26.86M | -70.57M | -16.64M | -17.38M |
| Depreciation & Amortization | 95K | 218K | 624K | 1.75M | 2.37M | 1.56M | 421K | 2.08M | 2.11M | 2.12M |
| Stock-Based Compensation | 2.3M | 12.71M | 14.73M | 23.54M | 4.08M | 2.24M | 447K | 1.22M | 54K | 207K |
| Deferred Taxes | 12K | 53K | 0 | 0 | 0 | 0 | 0 | 0 | 3.14M | -1.6M |
| Other Non-Cash Items | 54K | 153K | 255K | 406K | 279K | -6M | 2.88M | 53.73M | 2.24M | 6.51M |
| Working Capital Changes | -133K | -835K | -3.28M | -1.92M | 1.01M | -358K | 547K | -7.07M | -171K | 496K |
| Change in Receivables | -161K | -124K | -1.06M | 251K | 368K | 42K | 0 | -66K | 67K | -16K |
| Change in Inventory | -181K | -644K | -3.87M | -2.19M | 352K | -197K | -14K | 8K | -8K | -22K |
| Change in Payables | 124K | -47K | 699K | 407K | -961K | 627K | -879K | -550K | -234K | 186K |
| Cash from Investing | -210K | -547K | -582K | -16.03M | 15.93M | 3.8M | 21K | -61K | -67K | -51K |
| Capital Expenditures | -210K | -547K | -582K | -268K | -67K | -265K | -17K | -76K | -67K | -45K |
| CapEx % of Revenue | 3.51% | 9.32% | 9.3% | 3.72% | 25.87% | 1204.55% | 121.43% | 17.19% | 15.95% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 4.07M | 38K | 0 | 0 | -6K |
| Cash from Financing | 5.37M | 10.39M | 75.17M | -526K | 21.69M | 14.96M | 23.36M | 8.39M | 8.65M | 9.5M |
| Debt Issued (Net) | 108K | -44K | -82K | -338K | 1.71M | -265K | 0 | -357K | 1.49M | 44K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 37K | 1000K | 1000K | 1000K | 1000K | 1000K | 2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -3.56M | -225K | 99K | -301K | 4.46M | 505K | 1.19M | 3.92M |
| Net Change in Cash | 3.28M▲ 0% | 4.32M▲ 31.7% | 56.08M▲ 1199.3% | -49.73M▼ 188.7% | 9.32M▲ 118.7% | -8.86M▼ 195.1% | 814K▲ 109.2% | -12.29M▼ 1610.3% | -692K▲ 94.4% | -193K▲ 0% |
| Free Cash Flow | -2.1M▲ 0% | -6.07M▼ 189.6% | -19.09M▼ 214.5% | -33.44M▼ 75.2% | -28.37M▲ 15.2% | -27.89M▲ 1.7% | -22.59M▲ 19.0% | -20.7M▲ 8.4% | -9.34M▲ 54.9% | -9.66M▲ 0% |
| FCF Margin % | -35.07% | -103.41% | -305.1% | -464.52% | -10954.05% | -126772.73% | -161321.43% | -4682.13% | -2223.33% | -1323.84% |
| FCF Growth % | - | -189.6% | -214.5% | -75.18% | 15.16% | 1.7% | 19.02% | 8.37% | 54.88% | -19.57% |
| FCF per Share | -216.46 | -626.87 | -2585.32 | -3180.01 | -834.93 | -276.14 | -21.84 | -3.77 | -2.86 | -2.86 |
| FCF Conversion (FCF/Net Income) | 0.45x | 0.31x | 0.60x | 0.58x | 0.79x | 1.10x | 0.84x | 0.29x | 0.56x | 0.56x |
| Interest Paid | 3K | 4K | 11K | 49K | 28K | 2K | 0 | 204K | 31K | 12K |
| Taxes Paid | 1K | 1K | 5K | 30K | 0 | 2K | 3K | 0 | 0 | 0 |
VTAK Key Ratios
Catheter Precision, Inc. (VTAK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -104.36% | -114.08% | -132.77% | -144% | -234.29% | -463.48% | -101.02% | -269.53% |
| Return on Invested Capital (ROIC) | - | -721.3% | -342.25% | -219.54% | -1454.57% | - | -1027.79% | -58.82% | -58.82% |
| Gross Margin | 29.05% | 32.78% | -22.93% | -738.61% | -6990.91% | -1050% | 93.21% | 90% | 20.27% |
| Net Margin | -302.64% | -492.76% | -791.18% | -13916.99% | -113954.55% | -191892.86% | -15966.52% | -3962.62% | -2381.1% |
| Debt / Equity | - | 0.01x | 0.11x | 0.23x | 0.17x | - | 0.02x | 0.15x | 0.15x |
| Interest Coverage | -4440.00x | -2225.71x | -230.92x | -327.79x | -2926.60x | - | - | -123.55x | -62.72x |
| FCF Conversion | 0.31x | 0.60x | 0.58x | 0.79x | 1.10x | 0.84x | 0.29x | 0.56x | 0.56x |
| Revenue Growth | -1.77% | 6.59% | 15.06% | -96.4% | -91.51% | -36.36% | 3057.14% | -4.98% | 82.96% |
VTAK Frequently Asked Questions
Catheter Precision, Inc. (VTAK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Catheter Precision, Inc. (VTAK) reported $0.7M in revenue for fiscal year 2024. This represents a 88% decrease from $6.0M in 2016.
Catheter Precision, Inc. (VTAK) saw revenue decline by 5.0% over the past year.
Catheter Precision, Inc. (VTAK) reported a net loss of $17.4M for fiscal year 2024.
Dividend & Returns
Catheter Precision, Inc. (VTAK) has a return on equity (ROE) of -101.0%. Negative ROE indicates the company is unprofitable.
Catheter Precision, Inc. (VTAK) had negative free cash flow of $9.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More VTAK
Catheter Precision, Inc. (VTAK) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates